

IN THE CLAIMS

Please amend the Claims as follows:

---

E1

1. (AMENDED FOUR TIMES) A method of screening for a premalignant or neoplastic disease state in a cervical smear sample containing cells of the cervix, the method comprising contacting said sample with a panel of two or more monoclonal antibodies, wherein said panel binds to surface antigens on normal cells of the cervix in a pattern which represents normality, said panel including at least one monoclonal antibody specific for columnar cells and at least one monoclonal antibody specific for squamous cells, determining binding of said monoclonal antibodies to said sample and comparing the binding with a pattern of binding of said monoclonal antibodies to a normal cervical cell sample, wherein the percentage binding of the at least one monoclonal antibody specific for squamous cells to premalignant or neoplastic cells is decreased with respect to normal cells.

---

E2

3. (AMENDED THREE TIMES) A method of determining a premalignant or neoplastic disease state in a cervical smear sample containing cells of the cervix, the method comprising contacting a panel of two or more monoclonal antibodies with said sample, determining binding of said monoclonal antibodies to said sample and comparing the binding with a pattern of binding of said monoclonal antibodies to a normal cervical cell sample, wherein the percentage binding of the two or more monoclonal antibodies to premalignant or neoplastic cells is decreased with respect to normal cells, and wherein the panel includes one or more monoclonal antibodies comprising one or more polypeptides each comprising an antigen binding domain obtained from a hybridoma selected from those deposited at the European

Collection of Animal Cell Cultures (ECACC), under the accession numbers ECACC 95020718, ECACC 95020716, ECACC 95020720, ECACC 95020717 and ECACC 95020719.

- E-2
4. (AMENDED FOUR TIMES) A method according to Claim 1 wherein one or more of the monoclonal antibodies comprise a polypeptide able to bind to an antigen which can be bound by one or more antibodies obtained from a hybridoma selected from those deposited at the European Collection of Animal Cell Cultures (ECACC), under the accession numbers ECACC 95020718, ECACC 95020716, ECACC 95020720, ECACC 95020717 and ECACC 95020719.
- 

Please delete Claim 8.

Please add the following new Claims:

---

10. (NEWLY ADDED) The method as claimed in Claim 1 wherein said panel of monoclonal antibodies comprises a monoclonal antibody having an antigen binding domain obtainable from a hybridoma deposited at the European Collection of Animal Cell Cultures (ECACC) under the accession number ECACC 95020716.

E-3

11. (NEWLY ADDED) The method as claimed in Claim 1 wherein the surface antigens bound by said panel of monoclonal antibodies are not cytokeratins.

12. (NEWLY ADDED) The method as claimed in Claim 3 wherein said panel includes a monoclonal antibody comprising an antigen binding domain obtained from the hybridoma deposited under Accession Number ECACC 95020716.

---